Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:CNTB NASDAQ:CRMD NASDAQ:KYTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.21+0.8%$9.78$6.05▼$14.51$461.33M1.74836,803 shs981,344 shsCNTBConnect Biopharma$2.12-3.6%$2.53$0.77▼$3.82$138.52M-0.22208,491 shs339,268 shsCRMDCorMedix$8.65+1.3%$7.69$6.13▼$17.43$669.98M1.461.44 million shs1.41 million shsKYTXKyverna Therapeutics$7.85+1.8%$9.02$2.52▼$13.67$468.73M1.95858,637 shs729,362 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-3.64%-16.67%-29.28%-48.30%-5.05%CNTBConnect Biopharma+1.38%-5.98%-6.78%-21.15%+177.95%CRMDCorMedix+2.15%+1.07%+7.83%+27.08%-38.91%KYTXKyverna Therapeutics+3.21%-6.20%-17.54%-16.47%+127.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.21+0.8%$9.78$6.05▼$14.51$461.33M1.74836,803 shs981,344 shsCNTBConnect Biopharma$2.12-3.6%$2.53$0.77▼$3.82$138.52M-0.22208,491 shs339,268 shsCRMDCorMedix$8.65+1.3%$7.69$6.13▼$17.43$669.98M1.461.44 million shs1.41 million shsKYTXKyverna Therapeutics$7.85+1.8%$9.02$2.52▼$13.67$468.73M1.95858,637 shs729,362 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-3.64%-16.67%-29.28%-48.30%-5.05%CNTBConnect Biopharma+1.38%-5.98%-6.78%-21.15%+177.95%CRMDCorMedix+2.15%+1.07%+7.83%+27.08%-38.91%KYTXKyverna Therapeutics+3.21%-6.20%-17.54%-16.47%+127.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.46Hold$15.42113.82% UpsideCNTBConnect Biopharma 2.86Moderate Buy$7.20239.62% UpsideCRMDCorMedix 2.75Moderate Buy$15.0073.41% UpsideKYTXKyverna Therapeutics 2.67Moderate Buy$30.00282.17% UpsideCurrent Analyst Ratings BreakdownLatest CNTB, CRMD, ARVN, and KYTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026ARVNArvinas StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$18.006/3/2026KYTXKyverna Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.005/26/2026CNTBConnect Biopharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.005/26/2026ARVNArvinas Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/26/2026CNTBConnect Biopharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.005/21/2026CNTBConnect Biopharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$4.005/21/2026CNTBConnect Biopharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$4.005/19/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026CRMDCorMedix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/15/2026KYTXKyverna Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.00(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$262.60M1.77N/AN/A$6.76 per share1.07CNTBConnect Biopharma$60K2,224.59N/AN/A$0.75 per share2.83CRMDCorMedix$311.71M2.18$2.07 per share4.17$5.14 per share1.68KYTXKyverna TherapeuticsN/AN/AN/AN/A$3.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$80.80M-$3.32N/AN/AN/A-247.54%-44.38%-28.38%8/5/2026 (Estimated)CNTBConnect Biopharma-$55.48M-$1.15N/AN/AN/AN/A-122.29%-97.07%8/12/2026 (Estimated)CRMDCorMedix$163.05M$2.134.5248.06N/A45.25%45.57%24.76%8/6/2026 (Estimated)KYTXKyverna Therapeutics-$161.31M-$3.28N/AN/AN/AN/A-81.88%-64.87%8/11/2026 (Estimated)Latest CNTB, CRMD, ARVN, and KYTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million5/12/2026Q1 2026CNTBConnect Biopharma-$0.29-$0.34-$0.05-$0.34N/A$0.02 million5/12/2026Q1 2026KYTXKyverna Therapeutics-$0.75-$0.66+$0.09-$0.66N/AN/A5/11/2026Q1 2026ARVNArvinas-$0.95-$0.90+$0.05-$0.90$16.61 million$15.60 million3/31/2026Q4 2025CNTBConnect Biopharma-$0.30-$0.27+$0.03-$0.27$0.00 million($0.05) million3/26/2026Q4 2025KYTXKyverna Therapeutics-$0.80-$0.80N/A-$0.80N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A5.445.44CNTBConnect Biopharma0.013.233.23CRMDCorMedix0.332.972.74KYTXKyverna Therapeutics0.138.158.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%CNTBConnect Biopharma58.72%CRMDCorMedix34.18%KYTXKyverna Therapeutics18.08%Insider OwnershipCompanyInsider OwnershipARVNArvinas7.30%CNTBConnect Biopharma22.60%CRMDCorMedix3.50%KYTXKyverna Therapeutics17.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42064.52 million59.81 millionOptionableCNTBConnect Biopharma11062.96 million48.73 millionOptionableCRMDCorMedix3078.45 million75.71 millionOptionableKYTXKyverna Therapeutics9660.79 million50.10 millionOptionableCNTB, CRMD, ARVN, and KYTX HeadlinesRecent News About These CompaniesKyverna Therapeutics' (KYTX) Buy Rating Reaffirmed at HC WainwrightJune 4, 2026 | americanbankingnews.comKyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid ArthritisJune 3, 2026 | globenewswire.comKyverna Therapeutics Calls 2026 Pivotal as Shareholders Back Directors, AuditorJune 3, 2026 | americanbankingnews.comKyverna Therapeutics Stockholders Approve Directors and AuditorJune 2, 2026 | tipranks.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 31, 2026 | americanbankingnews.comKyverna Therapeutics (NASDAQ:KYTX) Downgraded to Sell Rating by Wall Street ZenMay 30, 2026 | americanbankingnews.comKyverna Therapeutics, Inc.: Kyverna Therapeutics Names Greg Martini as Chief Financial OfficerMay 19, 2026 | finanznachrichten.deKyverna Therapeutics Names Gregory Martini as New CFOMay 18, 2026 | tipranks.comKyverna Therapeutics Names Greg Martini as Chief Financial OfficerMay 18, 2026 | globenewswire.comKyverna Therapeutics to Present at Upcoming Investor ConferencesMay 14, 2026 | globenewswire.comKyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comEyeing CAR-T autoimmune first, Kyverna hires pharma veteran as CCOMay 5, 2026 | fiercepharma.comFKyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare ...May 4, 2026 | caledonianrecord.comCKyverna Therapeutics Appoints Chief Commercial Officer for GrowthMay 4, 2026 | tipranks.comKyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial OfficerMay 4, 2026 | globenewswire.comAs It Prepares BLA, Kyverna Shares Registrational CAR T Data in Stiff Person SyndromeApril 23, 2026 | precisionmedicineonline.comPKyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia GravisApril 22, 2026 | seekingalpha.comKyverna Shares Rise Premarket After Promising Trial of Neurological ProductApril 22, 2026 | marketwatch.comKyverna announces strong Phase 2/3 CAR T neuroimmunology dataApril 22, 2026 | tipranks.comKyverna Reports Positive Phase 2 Data in Stiff Person SyndromeApril 22, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNTB, CRMD, ARVN, and KYTX Company DescriptionsArvinas NASDAQ:ARVN$7.21 +0.06 (+0.84%) Closing price 04:00 PM EasternExtended Trading$7.18 -0.03 (-0.35%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Connect Biopharma NASDAQ:CNTB$2.12 -0.08 (-3.64%) Closing price 04:00 PM EasternExtended Trading$2.19 +0.07 (+3.35%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.CorMedix NASDAQ:CRMD$8.65 +0.11 (+1.29%) Closing price 04:00 PM EasternExtended Trading$8.61 -0.04 (-0.46%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Kyverna Therapeutics NASDAQ:KYTX$7.85 +0.14 (+1.82%) Closing price 04:00 PM EasternExtended Trading$7.74 -0.11 (-1.39%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
